Pharmacological characteristics and efficacy of a novel anti-angiogenic antibody FD006 in corneal neovascularization

BMC Biotechnology

Qun Wang⁴  Jing Yang³  Kun Tang²  Longlong Luo³  Liqiang Wang⁴  Lei Tian⁴  Yanming Jiang¹  Jiannan Feng³  Yan Li³  Beifen Shen³  Ming Lv³  Yifei Huang⁴ 

[1] Department of Ophthalmology, The second Artillery General Hospital, No.16 Xinwai Road, Xicheng District, Beijing 100088, China

[2] Department of Ophthalmology, Aerospace center Hospital, No. 15 Yuquan Road, Haidian District, Beijing 100049, China

[3] Institute of Basic Medical Sciences, Taiping Road, P.O. Box 130 (3), Beijing 100850, China

[4] Department of Ophthalmology, General Hospital of People’s Liberation Army, No.28 Fuxing Road, Haidian District, Beijing 100853, China

关键词: Anti-angiogenic treatment;    Angiogenesis;    Bevacizumab;    Cornea;    Neovascularization;   

Others  :  834897
DOI  :  10.1186/1472-6750-14-17

 received in 2013-12-16, accepted in 2014-02-24,  发布年份 2014

【 摘 要 】

Background

Vascular endothelial growth factor (VEGF) is a key angiogenic factors. It plays an important role in both physiologic and pathologic angiogenesis and increases permeability across the vessels. Using antibody phage display technology, we obtained a novel anti-VEGFA IgG, named as FD006. In this study, the pharmacological characteristics and efficacy of FD006 in corneal neovascularization (CoNV) were evaluated.

Results

FD006 was predicted to have similar binding mode to bevacizumab. Experimental analysis showed that the binding ability of FD006 seemed a little stronger than bevacizumab, for the EC50 of FD006 to bind VEGF analyzed by ELISA was about 0.037 μg/mL while that of bevacizumab was 0.18 μg/mL. Binding kinetics assays showed similar results that FD006 possessed 2-fold higher affinity to bind VEGF than bevacizumab due to slower dissociation rate of FD006; meanwhile, FD006 inhibited the VEGF-induced proliferation of HUVEC with an IC50 value of 0.031 ± 0.0064 μg/ml, which seemed similar or a litter better than bevacizumab (0.047 ± 0.0081 μg/ml). The subconjunctival administration of FD006, bevacizumab or dexamethasone could significantly inhibit the growth of CoNV contrasting to N.S (p < 0.01). At the early stage, FD006 showed better inhibitory effect on the growth of CoNV compared with bevacizumab (p < 0.05). Western blot analysis showed that FD006 could inhibit the expression of VEGF, VEGFR-1, VEGFR-2, MMP-9 and ICAM-1, which could explain its favorable anti-angiogenic activity.

Conclusions

The pharmacological characteristics of FD006 were similar or even a little better than bevacizumab in inhibiting corneal neovascularization.

【 授权许可】

   
2014 Wang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Beebe DC: Maintaining transparency: a review of the developmental physiology and pathophysiology of two avascular tissues. Semin Cell Dev Biol 2008, 19:125-133.
• [2]Chang JH, Gabison EE, Kato T, Azar DT: Corneal neovascularization. Curr Opin Ophthalmol 2001, 12:242-249.
• [3]Dana MR, Schaumberg DA, Kowal VO, Goren MB, Rapuano CJ, Laibson PR, Cohen EJ: Corneal neovascularization after penetrating keratoplasty. Cornea 1995, 14:604-609.
• [4]Haynes WL, Proia AD, Klintworth GK: Effect of inhibitors of aarachidonic acid metabolism on corneal neovascularization in the rat. Invest Ophthalmol Vis Sci 1989, 20:1588-1593.
• [5]Lipman RM, Epstein RJ, Hendricks RL: Suppression of corneal neovascularization with cyclosporine. Arch Ophthalmol 1992, 110:405-407.
• [6]Kruse FE, Joussen AM, Rohrschneider K, Becker MD, Volcker HE: Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 1998, 236:461-466.
• [7]Gohto Y, Obana A, Kanai M, Nagata S, Nakajima S, Miki T: Treatment parameters for selective occlusion of experimental corneal neovascularization by photodynamic therapy using a water soluble photosensitizer, ATX-S10(Na). Exp Eye Res 2001, 72(1):13-22.
• [8]Daya SM, Iiari FA: Living related conjunctival limbal allograft treatment of stem cell the deficiency. Ophthalmology 2001, 108:126-133.
• [9]Pillai CT, Dua HS, Hossain P: Fine needle diathermy occlusion of corneal vessels. Invest Opthalmol Vis Sci 2000, 41:2148-2153.
• [10]Philipp W, Speicher L, Humpel C: Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthamlol Vis Sci 2004, 41:2514-2522.
• [11]Joussen AM, Poulaki V, Mitsiades N, Stechschulte SU, Kirchhof B, Dartt DA, Fong GH, Rudge J, Wiegand SJ, Yancopoulos GD, Adamis AP: VEGF-dependent conjunctivalization of the corneal surface. Invest Ophthalmol Vis ScI 2003, 44:117-123.
• [12]Cursiefen C, Cao J, Chen L, Liu Y, Maruyama K, Jackson D, Kruse FE, Wiegand SJ, Dana MR, Streilein JW: Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 2004, 45(8):2666-2673.
• [13]Adamis AP, Shima DT: The role of vascular endothelial growth factor in ocular health and disease. Retina 2005, 25:111-118.
• [14]Ju M, Mailhos C, Bradley J, Dowie T, Ganley M, Cook G, Calias P, Lange N, Adamis AP, Shima DT, Robinson GS: Simultaneous but not prior inhibition of VEGF165 enhances the efficacy of photodynamic therapy in multiple models of ocular neovascularization. Invest Ophthalmol Vis Sci 2008, 49(2):662-670.
• [15]Finger PT, Chin KJ: Refractory squamous cell carcinoma of the conjunctiva treated with subconjunctival ranibizumab (Lucentis): a two-year study. Ophthal Plast Reconstr Surg 2012, 28(2):85-89.
• [16]Lai CM, Spilsbury K, Brankov M, Zaknich T, Rakoczy PE: Inhibition of corneal neovascularization by recombinant adenovirus mediated antisense VEGF RNA. Exp Eye Res 2002, 75(6):625-634.
• [17]Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 1997, 18:4-25.
• [18]Brown LF, Detmar M, Claffey K, Nagy JA, Feng D, Dvorak AM, Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 1997, 79:233-269.
• [19]Dastjerdi MH, Sadrai Z, Saban DR, Zhang Q, Dana R: Corneal penetration of topical and subconjunctival bevacizumab. Invest Ophthalmol Vis Sci 2011, 52(12):8718-8723.
• [20]Dastjerdi MH, Saban DR, Okanobo A, Nallasamy N, Sadrai Z, Chauhan SK, Hajrasouliha AR, Dana R: Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival. Invest Ophthalmol Vis Sci 2010, 51(5):2411-2417.
• [21]Carmona G, Chavakis E, Koehl U, Zeiher AM, Dimmeler S: Activation of Epac stimulates integrin-dependent homing of progenitor cells. Blood 2008, 111(5):2640-2646.
• [22]Okada N, Fukagawa K, Takano Y, Dogru M, Tsubota K, Fujishima H, Matsumoto K, Nakajima T, Saito H: The implications of the upregulation of ICAM-1/VCAM-1 expression of corneal fibroblasts on the pathogenesis of allergic keratopathy. Invest Ophthalmol Vis Sci 2005, 46(12):4512-4518.
• [23]Luo YZ, Guo ZH, Yu GZ, Qian JX, Gu XQ, Cao CW, Wang JJ: The Role of ICAM-1, VE-cadherin in Endothelial Progenitor Cells Taking Part in the Tumor Angiogenesis. J Oncol (Chinese) 2008, 8:651-653.
• [24]Muroski ME, Roycik MD, Newcomer RG, Van den Steen PE, Opdenakker G, Monroe HR, Sahab ZJ, Sang QX: Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Curr Pharm Biotechnol 2008, 9(1):34-46.
• [25]Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti G, Giavazzi R: Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 2003, 63(17):5224-5229.
• [26]Lamoreaux WJ, Fitzgerald ME, Reiner A, Hasty KA, Charles ST: Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res 1998, 55(1):29-42.
• [27]Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000, 2(10):737-744.
• [28]Hashimoto G, Inoki I, Fujii Y, Aoki T, Ikeda E, Okada Y: Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J Biol Chem 2002, 277(39):36288-36295.
• [29]Dauber-Osguthorpe P, Roberts VA, Osguthorpe DJ, Wolff J, Genest M, Hagler AT: Structure and energetics of ligand binding to proteins: Escherichia coli dihydrofolate reductase-trimethoprim, a drug-receptor system. Proteins 1988, 4(1):31-47.
• [30]Fuh G, Wu P, Liang WC, Ultsch M, Lee CV, Moffat B, Wiesmann C: Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem 2006, 281(10):6625-6631.